Olopatadine in Seasonal Allergic Conjunctivitis: Efficacy, Ocular Surface Safety, and Practical Considerations for Preservative-Free Multidose Therapy
- 1Department of Medicine and Health Science, University of Molise, 86100 Campobasso, Italy
Abstract
Background: Seasonal allergic conjunctivitis (SAC) is the most prevalent form of ocular allergy, characterized by recurrent episodes of IgE-mediated conjunctival inflammation triggered by seasonal aeroallergens (pollens). Its clinical course typically spans 4–12 weeks for individual pollen taxa and may extend considerably longer in polyallergic patients. Olopatadine hydrochloride ophthalmic solution, a selective H1-receptor antagonist with mast cell-stabilizing properties, is one of the most extensively studied topical antihistamines for SAC and is highly ranked in comparative evidence networks. Two clinically relevant aspects have received insufficient attention: the impact of benzalkonium chloride (BAK), a preservative, on the conjunctival surface, and the implications of bottle size for treatment adherence during SAC’s prolonged symptomatic periods. Methods: A non-systematic narrative review of the literature was conducted. PubMed was searched through 6 October 2026 using combinations of terms addressing seasonal and allergic conjunctivitis, olopatadine, benzalkonium chloride, preservative-free formulations, ocular surface, pollen season, polyallergy/polysensitization, adherence/compliance, multidose systems, contamination, and in-use shelf life. Randomized controlled trials, comparative clinical studies, systematic reviews, meta-analyses, and clinically relevant mechanistic, toxicological, and microbiological studies were prioritized; reference lists of key articles were also screened. No formal systematic-review or PRISMA selection process was applied. Because direct comparative evidence for preservative-free versus BAK-preserved olopatadine and for bottle-size effects on adherence is lacking, evidence from related ophthalmic formulations was considered indirect and interpreted accordingly. Results: In the most recent network meta-analysis, olopatadine 0.1% was highly ranked among topical antihistamines for SAC (SUCRA 0.88) and perennial allergic conjunctivitis (PAC; SUCRA 0.85). However, this ranking should be interpreted together with pairwise comparisons and study-design heterogeneity, including CAC-based evidence in which alcaftadine has shown greater reduction of ocular itch at early post-challenge time points. Olopatadine acts primarily at the conjunctival surface, with low systemic exposure after topical administration. Current evidence does not establish that BAK-mediated enhancement of intraocular drug delivery is required; however, in conventional multidose bottles, it serves an important antimicrobial-preservative function, and any preservative-free multidose presentation must rely on validated container technology and an adequate in-use shelf life. For olopatadine 0.1% BID, a larger bottle may reduce the number of dispensing events during prolonged symptomatic periods, but a direct adherence benefit has not been demonstrated. Conclusions: Olopatadine remains an established topical treatment for SAC. Preservative-free formulations may avoid preservative-related ocular-surface exposure, but direct head-to-head evidence demonstrating superior ocular-surface outcomes for preservative-free versus BAK-preserved olopatadine is currently unavailable. Likewise, a larger bottle may be practically useful for BID regimens when its validated in-use period permits prolonged use, although bottle size alone should not be considered a proven determinant of adherence. Formulation choice should therefore integrate efficacy, dosing frequency, ocular-surface tolerability, container technology, in-use shelf life, cost, and the expected duration of allergen exposure.
Related
- Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis
- Posterior Circulation Stroke in Patients With Dizziness: Diagnostic Challenges and Practical Considerations for Emergency Care
- Engaging children, adolescents and young adults living with rare diseases as research partners: practical considerations for meaningful involvement
- Treatment and practical considerations of IgA nephropathy.
- Systemic Therapies in Advanced Adrenocortical Carcinoma: Current Standards, Emerging Strategies, and Practical Considerations
BibTeX
@article{ciprandi2026olopatadine,
title = {{Olopatadine in Seasonal Allergic Conjunctivitis: Efficacy, Ocular Surface Safety, and Practical Considerations for Preservative-Free Multidose Therapy}},
author = {Giorgio Ciprandi},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207963},
url = {https://www.mdpi.com/2077-0383/15/20/7963},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Olopatadine in Seasonal Allergic Conjunctivitis: Efficacy, Ocular Surface Safety, and Practical Considerations for Preservative-Free Multidose Therapy
AU - Giorgio Ciprandi
PY - 2026
DA - 2026/10/15
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207963
UR - https://www.mdpi.com/2077-0383/15/20/7963
AB - Background: Seasonal allergic conjunctivitis (SAC) is the most prevalent form of ocular allergy, characterized by recurrent episodes of IgE-mediated conjunctival inflammation triggered by seasonal aeroallergens (pollens). Its clinical course typically spans 4–12 weeks for individual pollen taxa and may extend considerably longer in polyallergic patients. Olopatadine hydrochloride ophthalmic solution, a selective H1-receptor antagonist with mast cell-stabilizing properties, is one of the most extensively studied topical antihistamines for SAC and is highly ranked in comparative evidence networks. Two clinically relevant aspects have received insufficient attention: the impact of benzalkonium chloride (BAK), a preservative, on the conjunctival surface, and the implications of bottle size for treatment adherence during SAC’s prolonged symptomatic periods. Methods: A non-systematic narrative review of the literature was conducted. PubMed was searched through 6 October 2026 using combinations of terms addressing seasonal and allergic conjunctivitis, olopatadine, benzalkonium chloride, preservative-free formulations, ocular surface, pollen season, polyallergy/polysensitization, adherence/compliance, multidose systems, contamination, and in-use shelf life. Randomized controlled trials, comparative clinical studies, systematic reviews, meta-analyses, and clinically relevant mechanistic, toxicological, and microbiological studies were prioritized; reference lists of key articles were also screened. No formal systematic-review or PRISMA selection process was applied. Because direct comparative evidence for preservative-free versus BAK-preserved olopatadine and for bottle-size effects on adherence is lacking, evidence from related ophthalmic formulations was considered indirect and interpreted accordingly. Results: In the most recent network meta-analysis, olopatadine 0.1% was highly ranked among topical antihistamines for SAC (SUCRA 0.88) and perennial allergic conjunctivitis (PAC; SUCRA 0.85). However, this ranking should be interpreted together with pairwise comparisons and study-design heterogeneity, including CAC-based evidence in which alcaftadine has shown greater reduction of ocular itch at early post-challenge time points. Olopatadine acts primarily at the conjunctival surface, with low systemic exposure after topical administration. Current evidence does not establish that BAK-mediated enhancement of intraocular drug delivery is required; however, in conventional multidose bottles, it serves an important antimicrobial-preservative function, and any preservative-free multidose presentation must rely on validated container technology and an adequate in-use shelf life. For olopatadine 0.1% BID, a larger bottle may reduce the number of dispensing events during prolonged symptomatic periods, but a direct adherence benefit has not been demonstrated. Conclusions: Olopatadine remains an established topical treatment for SAC. Preservative-free formulations may avoid preservative-related ocular-surface exposure, but direct head-to-head evidence demonstrating superior ocular-surface outcomes for preservative-free versus BAK-preserved olopatadine is currently unavailable. Likewise, a larger bottle may be practically useful for BID regimens when its validated in-use period permits prolonged use, although bottle size alone should not be considered a proven determinant of adherence. Formulation choice should therefore integrate efficacy, dosing frequency, ocular-surface tolerability, container technology, in-use shelf life, cost, and the expected duration of allergen exposure.
SN - 2077-0383
ER -